In the 10 months since moving away from an exclusively virtual product development model, in-house R&D programmes have made a significant contribution to Nuformix’s product portfolio. Valuable gains in the speed and efficiency of development have been seen, and therefore Nuformix is expanding in-house capability to further accelerate growth of its product pipeline.
Nuformix’s CEO, Dan Gooding, explains “The virtues of lean and mean virtual pharma are well documented and have served us well, but more recently Nuformix has achieved major success taking R&D in-house. We’re able to operate both reactively and proactively when needed with increased speed and at a lower cost than working exclusively through partners. This increased autonomy has had an immediate impact on the value of our company and I’m excited to see how increasing this activity continues to impact our ability to develop new products over the next 6 months”.
CTO, Dr Joanne Holland adds “Focussing our in-house resources onto critical path R&D problems has been a great success. Whereas we will always need some degree of external support, I believe we have the right approach to broadening the scope of our future internal activity and that we will see the benefits of increased in-house efforts sooner rather than later”.